Erlotinib Hydrochloride Tablets 150?mg (Loruit) – EGFR Tyrosine Kinase Inhibitor for Oncology
$23.00
Erlotinib Hydrochloride (brand name Loruit®), a selective EGFR tyrosine kinase inhibitor, blocks EGFR-driven tumor growth. Supplied as 150?mg tablets (7 per box), manufactured by Shanghai Chnuo Pharmaceutical Co., Ltd. (NMPA No.?H20193262; Code?86900647000183; barcode?6973850270074). Strictly for laboratory research use?Please consult the staff for other purposes?
描述
Erlotinib Hydrochloride Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Erlotinib Hydrochloride Tablets (Loruit®) |
| Generic Name | Erlotinib HCl |
| Dosage Form | Oral film-coated tablet |
| Strength | 150?mg per tablet |
| Packaging | 7 tablets per box |
| Approval Number (NMPA) | H20193262 |
| Product Code | 86900647000183 |
| Manufacturer | Shanghai Chnuo Pharmaceutical Co., Ltd. |
| Barcode | 6973850270074 |
| CAS Number | 183321?74?6 |
| Molecular Formula | C??H??N?O?·HCl |
| Molecular Weight | ~429.9?g/mol |
| Mechanism Class | EGFR tyrosine kinase inhibitor |
| Pharmacokinetics | ~59% oral bioavailability; ~95% protein binding; ~36?h half-life |
| Metabolism/Excretion | CYP3A4 metabolism; >90% feces, ~9% urine |
| Storage | Store at 15–30?°C, protect from moisture/light |
| Intended Use | Laboratory research only — Not for clinical or veterinary use |
Erlotinib Hydrochloride Mechanism of Action
Erlotinib reversibly binds the ATP-binding site of EGFR, inhibiting its autophosphorylation and downstream signaling (PI3K/Akt, RAS/RAF/MEK/ERK), which reduces tumor proliferation and survival. It’s effective against both wild-type and mutant EGFR in NSCLC and pancreatic models.pubmed.ncbi.nlm.nih.gov+5ncbi.nlm.nih.gov+5go.drugbank.com+5
Research & Pharmacology Context
-
Approved by China’s NMPA (HJ20170143) since 2019, mirroring global approvals in NSCLC and pancreatic cancer.
-
STATPEARLS summarizes its use as a first- to third-line therapy in EGFR?mutant NSCLC and in combination with gemcitabine for pancreatic cancer.
-
Clinically relevant pharmacokinetics: ~59% bioavailability, 36?h half-life, high protein binding—ideal for research dose modeling.
Research Applications
-
NSCLC and pancreatic cancer models, especially those with EGFR mutations
-
Kinase pathway assays targeting EGFR phosphorylation and downstream signals
-
Drug interaction studies involving CYP3A4 substrates/inhibitors
-
Resistance research comparing erlotinib with osimertinib or combination therapies
-
PK/PD modeling and biomarker exploration relating to rash or biologic response
?? Research?Use Disclaimer
This product is for laboratory research and development use only. Not intended for clinical, diagnostic, therapeutic, or veterinary use.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Temozolomide Capsules 100?mg × 5 – ChuanNuo (MySean) | Research Grade Glioblastoma Drug
Temozolomide 100?mg capsules, 5?count box, produced by Shanghai ChuanNuo Pharmaceuticals Co., Ltd., approved under NMPA H20234716. A key alkylating agent for glioblastoma and astrocytoma research—ideal for preclinical oncology models.
?? For laboratory research or analytical use only – Not for human consumption or therapeutic use. $1.00 -
Rilertinib Mesylate Tablets (Sanrisso®) – 100?mg × 20 Tablets per Bottle
Rilertinib mesylate (Sanrisso®), developed by Nanjing Sanhome Pharmaceutical Co., Ltd., is a third-generation EGFR-TKI approved by China's NMPA (Approval No. H20240020; Drug Code: 86901583000930). Each bottle contains 20 tablets of 100?mg each. Strictly for laboratory research use only—not for clinical or human use. $1.00 -
Cetuximab NO1 Injection 100?mg/50?mL (Datalai) by Kelun Botai | EGFR?Targeted Biologic | Price comparison
Cetuximab NO1 Injection, 100?mg in 50?mL vial, is a biosimilar developed by Sichuan Kelun Botai Biopharma, branded as Datalai®. Approved in China (NMPA S20250006), this EGFR-targeting monoclonal antibody is ideal for laboratory or analytical research in oncology.
?? For laboratory research use only – Not for human consumption or therapeutic use. $1.00 -
Regorafenib Tablets (Reodixin®) – 40?mg
Regorafenib (Reodixin®) is an oral multi-kinase inhibitor targeting angiogenesis, proliferation, metastasis, and tumor immunity. FDA-approved for several advanced solid tumors. Here offered as 40?mg tablets in a 28-count bottle—strictly for laboratory research use only $1.00
评价
目前还没有评价